HBM (HBM)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 6/9, Altman Z 2.5. Beneish M-Score of -2.13 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe capital allocation efficiency for HBM presents a critical constraint, as the return on invested capital of 15.8% falls short of the weighted average cost of capital at 16.3%, resulting in a negative spread that erodes intrinsic value creation despite robust profitability metrics. While the DuPont decomposition reveals exceptional operational leverage with net margins expanding to 25.7% and gross margins holding steady at 33.6%, this high-margin profile is not being sufficiently capitalized by growth, evidenced by revenue expansion of only 9.4%. Financial health indicators remain mixed; a Piotroski F-Score of 6/9 suggests moderate financial strength with room for improvement in quality trends, whereas the Altman Z-Score of 2.5 indicates proximity to distress territory that warrants scrutiny against the benign Beneish M-Score of -2.13, which points toward low earnings manipulation risk.
Valuation dynamics currently reflect a significant divergence between market pricing and fundamental fair value estimates derived from discounted cash flow modeling. Trading at approximately 13.4x forward earnings, the stock appears materially undervalued relative to its calculated DCF fair value of $7 per share, implying that current market consensus may be underestimating future cash flow potential or discounting growth too aggressively given the historical margin profile. This discrepancy suggests a market premium is being demanded for perceived execution risks rather than fundamental solvency issues, creating a scenario where price action could diverge sharply from intrinsic worth if operational efficiency improves to align ROIC above WACC.
Risk assessment highlights a tension between earnings quality and capital productivity; while the low Beneish M-Score mitigates concerns over accounting aggressiveness, the negative ROIC-WACC spread acts as a drag on shareholder returns regardless of margin expansion. The combination of moderate Piotroski fundamentals and an Altman Z-Score hovering near the danger zone suggests that downside volatility could be triggered by any deterioration in working capital management or revenue velocity, potentially keeping valuation multiples compressed until operational efficiency metrics turn positive.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 14.3% | 16.3% | 18.3% |
|---|---|---|---|
| 2% | $8 | $7 | $6 |
| 3% | $9 | $7 | $6 |
| 4% | $10 | $8 | $7 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=16.3%, terminal growth 3%. Fair value $7 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like VSS or SPDW, the fund manager is mechanically forced to buy or sell HBM shares regardless of HBM's individual fundamentals. We estimate $38M of passive capital is structurally linked to HBM through 2 tracked ETFs. Passive flows have a limited but growing influence on HBM's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 2 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in HBM to visualize passive redemption contagion across ETFs and collateral stocks.
If HBM (HBM) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies SAMSUNG ELECTR GDR REG S (SMSN) as the most exposed collateral stock, sharing 1 ETFs with HBM. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 2 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
HBM Ownership Dynamics
ETFs with Highest HBM Exposure
Float lock-up computed from 2 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
HBM Capital Efficiency
How efficiently does HBM convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
HBM converts 16% of its EBITDA into free cash flow, a low conversion rate suggesting heavy reinvestment. This may indicate a growth phase (building capacity) or structural capital intensity. The 84% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-0.5%), suggesting reinvested capital is destroying shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-11 | 1,300 | $25.02 | $32,526 |
| 2026-05-05 | 28,057 | $21.77 | $610,800.89 |
| 2026-05-01 | 27,736 | $23.11 | $640,978.96 |
| 2026-04-30 | 69,292 | $22.46 | $1.6M |
| 2026-04-28 | 1,247 | $24.41 | $30,439.27 |
| 2026-04-27 | 12,343 | $24.35 | $300,552.05 |
| 2026-04-24 | 78,716 | $24.02 | $1.9M |
| 2026-04-23 | 246,749 | $24.69 | $6.1M |
| 2026-04-21 | 92,304 | $25.67 | $2.4M |
| 2026-04-20 | 157,842 | $25.88 | $4.1M |
| 2026-04-17 | 12,805 | $24.92 | $319,100.6 |
| 2026-04-14 | 1,477 | $24.41 | $36,053.57 |
| 2026-04-10 | 82 | $23.47 | $1,924.54 |
| 2026-04-09 | 7,444 | $23.78 | $177,018.32 |
| 2026-04-06 | 954 | $21.64 | $20,644.56 |
| 2026-04-02 | 980 | $22.00 | $21,560 |
| 2026-03-31 | 484 | $19.05 | $9,220.2 |
| 2026-03-24 | 5,341 | $18.85 | $100,677.85 |
| 2026-03-23 | 13,160 | $18.08 | $237,932.8 |
| 2026-03-20 | 1,746 | $18.65 | $32,562.9 |
| 2026-03-17 | 30,396 | $21.14 | $642,571.44 |
| 2026-03-16 | 7,163 | $20.73 | $148,488.99 |
| 2026-03-13 | 14,177 | $21.85 | $309,767.45 |
| 2026-03-09 | 970 | $22.29 | $21,621.3 |
| 2026-03-04 | 1,845,734 | $24.94 | $46.0M |
| 2026-03-02 | 6,852 | $28.33 | $194,117.16 |
| 2026-02-27 | 41,938 | $28.03 | $1.2M |
| 2026-02-24 | 20,989 | $26.06 | $546,973.34 |
| 2026-02-23 | 1,725 | $24.98 | $43,090.5 |
| 2026-02-20 | 30,514 | $24.74 | $754,916.36 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare HBM to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.